Stock XNCR XENCOR, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Xencor, Inc.

Equities

XNCR

US98401F1057

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
19.98 USD +3.90% Intraday chart for Xencor, Inc. +8.71% -5.89%
Apr. 16 BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating MT
Apr. 09 Xencor Names Bart Cornelissen as Chief Financial Officer MT

Business Summary

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Number of employees: 280

Sales per Business

USD in Million2022Weight2023Weight Delta
Monoclonal Bispecific Antibody and Cytokine Therapeutics
100.0 %
165 100.0 % 168 100.0 % +2.28%

Sales per region

USD in Million2022Weight2023Weight Delta
Global
100.0 %
165 100.0 % 168 100.0 % +2.28%

Managers

Managers TitleAgeSince
Bassil Dahiyat FOU
 Founder 53 97-07-31
John Desjarlais CTO
 Chief Tech/Sci/R&D Officer 59 01-06-30
Charles Liles IRC
 Investor Relations Contact - -
Jennifer Sandoz HRO
 Human Resources Officer - -
Celia Eckert LAW
 General Counsel 52 19-09-09
Jeremy Grunstein PRN
 Corporate Officer/Principal - 19-05-22
David Szymkowski PRN
 Corporate Officer/Principal 60 01-12-31
Raphael Clynes PRN
 Corporate Officer/Principal - 17-06-07
Nancy Valente PRN
 Corporate Officer/Principal 66 22-09-07
Dane Leone PRN
 Corporate Officer/Principal - Jan. 01

Members of the board

Members of the board TitleAgeSince
Kevin Gorman BRD
 Director/Board Member 66 17-04-13
Richard J. Ranieri BRD
 Director/Board Member 71 17-12-18
Alan Bruce Montgomery BRD
 Director/Board Member 70 15-03-17
Bassil Dahiyat FOU
 Founder 53 97-07-31
Kurt Gustafson BRD
 Director/Board Member 56 14-07-24
Ellen Feigal
69 -
Barbara Klencke BRD
 Director/Board Member 66 23-09-14
Dagmar Rosa-Bjorkeson BRD
 Director/Board Member 60 19-12-17
Nancy Valente PRN
 Corporate Officer/Principal 66 22-09-07

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 61,647,493 61,064,703 ( 99.05 %) 0 99.05 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
17.83 %
10,897,006 17.83 % 241 M $
PRIMECAP Management Co.
14.56 %
8,901,607 14.56 % 197 M $
Vanguard Fiduciary Trust Co.
11.07 %
6,767,249 11.07 % 150 M $
EcoR1 Capital, LLC
8.643 %
5,282,516 8.643 % 117 M $
T. Rowe Price International Ltd.
5.700 %
3,483,775 5.700 % 77 M $
STATE STREET CORPORATION
5.443 %
3,326,856 5.443 % 74 M $
Fidelity Management & Research Co. LLC
4.193 %
2,562,905 4.193 % 57 M $
Armistice Capital LLC
2.454 %
1,500,000 2.454 % 33 M $
T. Rowe Price Investment Management, Inc.
2.211 %
1,351,367 2.211 % 30 M $
Geode Capital Management LLC
2.151 %
1,314,943 2.151 % 29 M $

Holdings

NameEquities%Valuation
INMUNE BIO, INC.
10.46%
 1,885,533 10.46% 22,155,013 $

Company contact information

Xencor, Inc.

465 North Halstead Street Suite 200

91016, Pasadena

+626 305 5900

http://www.xencor.com
address Xencor, Inc.(XNCR)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Xencor, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
19.98 USD
Average target price
36.18 USD
Spread / Average Target
+81.09%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
XENCOR, INC. Stock Xencor, Inc.
-5.89% 1.23B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XNCR Stock
  4. Company Xencor, Inc.